期刊
NATURE
卷 605, 期 7911, 页码 640-652出版社
NATURE PORTFOLIO
DOI: 10.1038/s41586-022-04690-5
关键词
-
资金
- Institute of MGH,
- MIT
- Harvard
- Massachusetts Consortium on Pathogen Readiness (MassCPR)
- National Institutes of Health (NIH) [3R37AI080289-11S1, R01AI146785, U19AI42790-01, U19AI135995-02, AI134907]
- Gates Foundation Global Health Vaccine Accelerator Platform funding [OPP1146996, INV-001650]
- Musk Foundation
- National Institute of Allergy and Infectious Diseases (NIAID)/NIH Collaborative Influenza Vaccine Innovation Centers (CIVIC) [75N93019C00050]
- Duke University
- NIH/NIAID CIVIC [75N93019C00051]
- Icahn School of Medicine at Mount Sinai
- NIH/NIAID Center for Influenza Vaccine Research for High-Risk Populations (CIVR-HRP) CIVIC [75N93019C0052]
- University of Georgia
- NIH/NIAID Centers of Excellence for Influenza Research and Response (CEIRR) [75N93021C00014]
- NIH\NIAID CEIRR [75N9302100016]
- St Jude Children's Research Hospital
- NIH/NIAID CEIRR [75N93021C00017]
- Emory University
- NIH/NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) [HHSN272201400006C]
- NIH/NIAID CEIRS [HHS N2772201400007C, HHSN272201400008C]
- Johns Hopkins University
- Investigator of the Howard Hughes Medical Institute
- Intramural NIH Research Program project [ZIA AI005156-02]
- NIH/NIAID [75N93019D0025]
- Intramural Research Program of the NIAID, NIH
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- US Department of the Army [W81XWH-18-2-0040]
- Intramural Research Program of the Vaccine Research Center, NIAID and NIH
- German Ministry of research under project codes DZIF
- MolTrax
- PREPARED
- NIAID [U01AI141990, 1U01AI150747, HHSN272201800013C]
- NIH\NIAID [P51OD011132, 3U19AI057266-17S1]
- Emory Executive Vice President for Health Affairs Synergy Fund award
- Woodruff Health Sciences Center 2020 COVID-19 CURE Award, Agod
- VEO, versatile emerging infectious disease observatory: forecasting, nowcasting and tracking in a changing world
- European Union's Horizon 2020 research and innovation programme [874735]
- ZonMw [10150062010005, APW 202645827]
- WHO [APW 202605269]
- Los Alamos National Laboratory
- Gates Foundation [OPP1169339]
- Sealy Smith Foundation
- Kleberg Foundation
- John S. Dunn Foundation
- Amon G. Carter Foundation
- Gillson Longenbaugh Foundation
- Summerfield Robert Foundation
- NIH/NCI: Serological Sciences Network (SeroNet) [75N91019D00024]
- NIH, NIAID [75N93019C00076]
- US Food and Drug Administration institutional research funds
- NIH [R24 AI120942]
- Sealy and Smith Foundation
- [HHSN272201700060C]
- [3R01AI148378-01S1]
- [R01AI141707]
- [U01AI151810]
- [R01AI157155]
- [1R01AI143639]
- [R01AI20997]
- [UM1AI068618]
- [R01AI153602]
- [P01AI060699]
- [R01AI129269]
- [U01AI144616]
- [U01AI150747]
- [R01AI136514]
- [R01AI154470]
- Bill and Melinda Gates Foundation [OPP1169339, INV-001650] Funding Source: Bill and Melinda Gates Foundation
The SAVE program is a real-time risk assessment initiative established by the National Institute of Allergy and Infectious Diseases to address the public health threat posed by the emergence of SARS-CoV-2 variants. Its goal is to evaluate the potential impact of these variants on transmission, virulence, and immunity induced through infection or vaccination.
The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or vaccination. To address the public health threat caused by the increasing SARS-CoV-2 genomic diversity, the National Institute of Allergy and Infectious Diseases within the National Institutes of Health established the SARS-CoV-2 Assessment of Viral Evolution (SAVE) programme. This effort was designed to provide a real-time risk assessment of SARS-CoV-2 variants that could potentially affect the transmission, virulence, and resistance to infection- and vaccine-induced immunity. The SAVE programme is a critical data-generating component of the US Government SARS-CoV-2 Interagency Group to assess implications of SARS-CoV-2 variants on diagnostics, vaccines and therapeutics, and for communicating public health risk. Here we describe the coordinated approach used to identify and curate data about emerging variants, their impact on immunity and effects on vaccine protection using animal models. We report the development of reagents, methodologies, models and notable findings facilitated by this collaborative approach and identify future challenges. This programme is a template for the response to rapidly evolving pathogens with pandemic potential by monitoring viral evolution in the human population to identify variants that could reduce the effectiveness of countermeasures. The SARS-CoV-2 Assessment of Viral Evolution (SAVE) programme provides a real-time risk assessment of SARS-CoV-2 variants with the potential to affect transmission, virulence and resistance to infection- and vaccine-induced immunity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据